Korean Journal of Clinical Pharmacy (한국임상약학회지)

Korean College Of Clinical Pharmacy (한국임상약학회)
권호 표지

Analysis of Healthcare Personnel's Clinical Beliefs and Knowledge behind Overutilization of Stress Ulcer Prophylaxis in Hospitalized Patients

스트레스성 위장궤양 예방치료제 처방남용에 대한 의료전문가의 인식과 지식 분석

  • 노유진 (아주대학교 약학대학) ;
  • 이재명 (아주대학교 의과대학 외과학교실) ;
  • 신수영 (아주대학교 약학대학)
  • Received : 2015.06.27
  • Accepted : 2015.10.20
  • Published : 2015.12.31
Download PDF
⟨ Previous Next ⟩

Abstract

Background: The over-prescription of acid-suppressive therapy for the provision of stress ulcer prophylaxis (SUP) in hospitalized patients has been identified in a proceeding study. Objective: This study was conducted to evaluate clinicians' beliefs, knowledge and other factors that influence the over-prescribing of SUP in low-risk, non-intensive care unit (non-ICU) patients. Method: A cross-sectional survey consisting of multiple-choice queries and close-ended questions was distributed to healthcare personnel at a major teaching hospital in Korea. Results: More than half of total respondents reported that they would continue SUP following patients discharge from the ICU (77.8%, 43.5%, and 39.7% in the physician, pharmacist, and nurse groups, respectively). Over 55% of physicians would also initiate non-ICU patients on SUP upon hospital admission, and 42.6% of physicians would even continue prophylaxis post hospital discharge. The mean knowledge score regarding SUP indications and side effects was higher in pharmacists compared to physicians and nurses (12.44, 7.40, and 7.28, respectively; p<0.001). High-prescribing behavior was associated with a prescriber's belief that SUP is effective for preventing bleeding (odds ratio 7.40; 95% confidence interval 1.57 to 31.94; p=0.012). Low knowledge score and computerized order set also showed statistically significant association with the overutilization of SUP.

Keywords

References

  1. Grube RR, May DB. Stress ulcer prophylaxis in hospitalized patients not in intensive care units. Am J Health Syst Pharm 2007;64(13):1396-1400. https://doi.org/10.2146/ajhp060393
  2. ASHP Therapeutic Guidelines on Stress Ulcer Prophylaxis. ASHP Commission on Therapeutics and approved by the ASHP Board of Directors on November 14, 1998. Am J Health Syst Pharm 1999; 56(4):347-79.
  3. Choung RS, Talley NJ. Epidemiology and clinical presentation of stress-related peptic damage and chronic peptic ulcer. Curr Mol Med 2008;8:253-57. https://doi.org/10.2174/156652408784533823
  4. Andersson B, Nilsson J, Brandt J, Hoglund P, Andersson R. Gastrointestinal complications after cardiac surgery. Br J Surg 2005;92: 326-33. https://doi.org/10.1002/bjs.4823
  5. Faisy C, Guerot E, Diehl JL, et al. Clinically significant gastrointestinal bleeding in critically ill patients with and without stress-ulcer prophylaxis. Intensive Care Med 2003;29(8):1306-13. https://doi.org/10.1007/s00134-003-1863-3
  6. Dellinger RP, Levy MM, Rhodes A, et al. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock, 2012. Intensive Care Med 2013;39(2):165-228. https://doi.org/10.1007/s00134-012-2769-8
  7. Spirt MJ, Stanley S. Update on stress ulcer prophylaxis in critically ill patients. Crit Care Nurse 2006;26(1):18-20, 22-18; quiz 29.
  8. Cook DJ, Griffith LE, Walter SD, et al. The attributable mortality and length of intensive care unit stay of clinically important gastrointestinal bleeding in critically ill patients. Crit Care 2001;5(6):368-75. https://doi.org/10.1186/cc1071
  9. Thomas L, Culley EJ, Gladowski P, et al. Longitudinal analysis of the costs associated with inpatient initiation and subsequent outpatient continuation of proton pump inhibitor therapy for stress ulcer prophylaxis in a large managed care organization. J Manag Care Pharm 2010;16(2): 122-9.
  10. Herzig SJ, Vaughn BP, Howell MD, et al. Acid-suppressive medication use and the risk for nosocomial gastrointestinal tract bleeding. Arch Intern Med 2011;171(11):991-97.
  11. Heidelbaugh JJ, Inadomi JM. Magnitude and economic impact of inappropriate use of stress ulcer prophylaxis in non-ICU hospitalized patients. Am J Gastroenterol 2006;101(10):2200-2205. https://doi.org/10.1111/j.1572-0241.2006.00839.x
  12. Gardner TB, Robertson DJ. Stress ulcer prophylaxis in non-critically ill patients: less may be more. Am J Gastroenterol 2006;101(10):2206-2208. https://doi.org/10.1111/j.1572-0241.2006.00847.x
  13. Nardino RJ, Vender RJ, Herbert PN. Overuse of acid-suppressive therapy in hospitalized patients. Am J Gastroenterol 2000;95(11):3118-22. https://doi.org/10.1016/S0002-9270(00)02052-9
  14. Shin S. Evaluation of costs accrued through inadvertent continuation of hospital-initiated proton pump inhibitor therapy for stress ulcer prophylaxis beyond hospital discharge: a retrospective chart review. Ther Clin Risk Manag 2015;11:649-57.
  15. Cook DJ, Fuller HD, Guyatt GH, et al. Risk factors for gastrointestinal bleeding in critically ill patients. Canadian Critical Care Trials Group. N Engl J Med 1994;330(6):377-81. https://doi.org/10.1056/NEJM199402103300601
  16. Alhazzani W, Alenezi F, Jaeschke RZ, et al. Proton pump inhibitors versus histamine 2 receptor antagonists for stress ulcer prophylaxis in critically ill patients: a systematic review and meta-analysis. Crit Care Med 2013;41(3):693-705. https://doi.org/10.1097/CCM.0b013e3182758734
  17. Lin PC, Chang CH, Hsu PI, et al. The efficacy and safety of proton pump inhibitors vs histamine-2 receptor antagonists for stress ulcer bleeding prophylaxis among critical care patients: a meta-analysis. Crit Care Med 2010;38(4):1197-1205. https://doi.org/10.1097/CCM.0b013e3181d69ccf
  18. Barkun AN, Bardou M, Pham CQ, et al. Proton pump inhibitors vs. histamine 2 receptor antagonists for stress-related mucosal bleeding prophylaxis in critically ill patients: a meta-analysis. Am J Gastroenterol 2012;107(4):507-20; quiz 521. https://doi.org/10.1038/ajg.2011.474
  19. Barletta JF, Sclar DA. Use of proton pump inhibitors for the provision of stress ulcer prophylaxis: clinical and economic consequences. Pharmacoeconomics 2014;32(1):5-13. https://doi.org/10.1007/s40273-013-0119-5
  20. Zeigler AJ, McAllen KJ, Slot MG, et al. Medication reconciliation effect on prolonged inpatient stress ulcer prophylaxis. Ann Pharmacother 2008;42(7):940-46. https://doi.org/10.1345/aph.1L123
  21. Murphy CE, Stevens AM, Ferrentino N, et al. Frequency of inappropriate continuation of acid suppressive therapy after discharge in patients who began therapy in the surgical intensive care unit. Pharmacotherapy 2008;28(8):968-76. https://doi.org/10.1592/phco.28.8.968
  22. Wohlt PD, Hansen LA, Fish JT. Inappropriate continuation of stress ulcer prophylactic therapy after discharge. Ann Pharmacother 2007; 41(10):1611-16. https://doi.org/10.1345/aph.1K227
  23. Hatch JB, Schulz L, Fish JT. Stress ulcer prophylaxis: reducing nonindicated prescribing after hospital discharge. Ann of Pharmacother 2010;44(10):1565-71. https://doi.org/10.1345/aph.1P167
  24. Hussain S, Stefan M, Visintainer P, et al. Why do physicians prescribe stress ulcer prophylaxis to general medicine patients? South Med J 2010;103(11):1103-10. https://doi.org/10.1097/SMJ.0b013e3181f6539d
  25. Koczka CP, Geraldino-Pardilla LB, Goodman AJ. Physicians' opinions of stress ulcer prophylaxis: survey results from a large urban medical center. Dig Dis Sci 2013;58(3):777-81. https://doi.org/10.1007/s10620-012-2423-x
  26. Dial S, Delaney JA, Barkun AN, et al. Use of gastric acid-suppressive agents and the risk of community-acquired Clostridium difficile-associated disease. JAMA 2005;294(23):2989-95. https://doi.org/10.1001/jama.294.23.2989
  27. Dial S, Delaney JA, Schneider V, et al. Proton pump inhibitor use and risk of community-acquired Clostridium difficile-associated disease defined by prescription for oral vancomycin therapy. CMAJ 2006; 175(7):745-48. https://doi.org/10.1503/cmaj.060284
  28. Cook DJ. Stress ulcer prophylaxis: gastrointestinal bleeding and nosocomial pneumonia. Best evidence synthesis. Scand J Gastroenterol Suppl 1995;210:48-52.
  29. Laheij RJ, Sturkenboom MC, Hassing RJ, et al. Risk of communityacquired pneumonia and use of gastric acid-suppressive drugs. JAMA 2004;292(16):1955-60. https://doi.org/10.1001/jama.292.16.1955
  30. Herzig SJ, Howell MD, Ngo LH, et al. Acid-suppressive medication use and the risk for hospital-acquired pneumonia. JAMA 2009;301(20): 2120-28. https://doi.org/10.1001/jama.2009.722
  31. Laine L. Proton pump inhibitors and bone fractures? Am J Gastroenterol 2009;104 Suppl 2:S21-26. https://doi.org/10.1038/ajg.2009.48
  32. Yang YX. Proton pump inhibitor therapy and osteoporosis. Curr Drug Saf 2008;3(3):204-209. https://doi.org/10.2174/157488608785699414
  33. Jayatilaka S, Shakov R, Eddi R, et al. Clostridium difficile infection in an urban medical center: five-year analysis of infection rates among adult admissions and association with the use of proton pump inhibitors. Ann Clin Lab Sci 2007;37(3):241-7.
  34. Thorens J, Froehlich F, Schwizer W, et al. Bacterial overgrowth during treatment with omeprazole compared with cimetidine: a prospective randomised double blind study. Gut 1996;39(1):54-59. https://doi.org/10.1136/gut.39.1.54
  35. Zedtwitz-Liebenstein K, Wenisch C, Patruta S, et al. Omeprazole treatment diminishes intra- and extracellular neutrophil reactive oxygen production and bactericidal acitivity. Crit Care Med 2002;30(5):1118-22. https://doi.org/10.1097/00003246-200205000-00026
  36. Tasaka CL, Burg C, VanOsdol SJ, et al. An interprofessional approach to reducing the overutilization of stress ulcer prophylaxis in adult medical and surgical intensive care units. Ann Pharmacother 2014;48(4): 462-69. https://doi.org/10.1177/1060028013517088
  37. Pitimana-aree S, Forrest D, Brown G, et al. Implementation of a clinical practice guideline for stress ulcer prophylaxis increases appropriateness and decreases cost of care. Intensive Care Med 1998;24(3):217-23. https://doi.org/10.1007/s001340050553
  38. Khalili H, Dashti-Khavidaki S, Hossein Talasaz AH, et al. Descriptive analysis of a clinical pharmacy intervention to improve the appropriate use of stress ulcer prophylaxis in a hospital infectious disease ward. J Manag Care Pharm 2010;16(2):114-121